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Molecular and epidemiologic investigations suggest a causal role for human papillomavirus (HPV) in 
anogenital cancers.  This study identiﬁ ed oncogenic HPV genotypes in anogenital cancers among men 
and women in a 2013 cross-sectional descriptive study in Myanmar.  In total,  100 biopsy tissues of his-
tologically conﬁ rmed anogenital cancers collected in 2008-2012 were studied,  including 30 penile and 9 
anal cancers from Yangon General Hospital and 61 vulvar cancers from Central Women’s Hospital,  
Yangon.  HPV-DNA testing and genotyping were performed by polymerase chain reaction-restriction 
fragment length polymorphism.  Overall,  34  of anogenital cancers were HPV-positive.  HPV was 
found in 44.4  of anal (4/9),  36.1  of vulvar (22/61),  and 26.7  of penile (8/30) cancers.  The most 
frequent genotypes in anal cancers were HPV 16 (75 ) and 18 (25 ).  In vulvar cancers,  HPV 33 was 
most common (40.9 ),  followed by 16 (31.8 ),  31 (22.7 ),  and 18 (4.6 ).  In penile cancers,  HPV 16 
(62.5 ) was most common,  followed by 33 (25 ) and 18 (12.5 ).  This is the ﬁ rst report of evidence-
based oncogenic HPV genotypes in anogenital cancers among men and women in Myanmar.  This 
research provides valuable information for understanding the burden of HPV-associated cancers of the 
anus,  penis,  and vulva and considering the eﬀ ectiveness of prophylactic HPV vaccination.
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H uman papillomavirus (HPV) infection is a nec-essary cause of all cervical cancers and is etio-
logically related to a subset of cancers of the anus,  
oropharynx,  penis,  vagina,  and vulva [1-3].  Overall,  
5.2  of all cancers worldwide can be attributed to 
HPV infection [4].  The World Health Organization 
(WHO) reported that cervical cancer is the second 
most common cancer in women living less developed 
regions with an estimated 445,000 new cases in 2012 
(84  of the new cases worldwide) www.who.int/medi-
acentre/factsheets/fs380/en/).
　 Anogenital HPV infection is one of the most com-
monly diagnosed sexually transmitted infections world-
wide.  Anogenital HPV types have been classiﬁ ed into 
low-risk (non-oncogenic) and high risk (oncogenic) 
types.  Low risk types are associated with anogenital 
warts (condyloma acuminatum),  oral and conjunctival 
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papillomas,  recurrent respiratory papillomatosis (in 
infants and young children),  and mild dysplasia [5].  
High-risk types are associated with high-grade dyspla-
sia and various cancers.
　 Although the incidence and prevalence of HPV at 
sites such as the anus,  penis,  vagina,  and vulva are at 
least as common as those at the cervix [6-7],  the 
incidence of cervical cancer is much higher than that 
of non-cervical cancers.  At non-cervical sites,  the 
HPV-positive subset displays unique pathologic,  
molecular,  epidemiologic,  and clinical features.
　 The variability in HPV-attributable proportions for 
non-cervical cancers arises from diﬀ erences in HPV 
detection methods across studies as well as from true 
geographic diﬀ erences in HPV-attributable propor-
tions.  Despite this variability,  90-93  of anal can-
cers,  12-63  of oropharyngeal cancers,  36-40  of 
penile cancers,  40-64  of vaginal cancers,  and 
40-51  of vulvar cancers are potentially attributable 
to HPV infection.  Notably,  high proportions of cervi-
cal and non-cervical HPV-related cancers (70-76  
and 63-95 ,  respectively) are attributable to onco-
genic HPV types 16 and 18,  which are targeted by 
currently available quadrivalent and bivalent prophy-
lactic HPV vaccines [3].
　 Worldwide,  there are about 97,215 cases of non-
cervical cancers annually,  including 50,780 cancers 
among men (13,485 anal cancers,  26,775 oropharyn-
geal cancers,  and 10,520 penile cancers) and 46,435 
cancers among women (14,787 anal cancers,  6,048 
oropharyngeal cancers,  and 25,600 vaginal/vulvar 
cancers) [8].
　 In a report by Serrano B et al.,  the prevalence of 
HPV DNA were 84.9 ,  28.6 ,  74.3 ,  and 90.0  
for invasive cervical,  vulvar,  vaginal,  and anal can-
cers,  respectively.  HPV 16 was the most frequent 
type in all lesions.  Variations in the RC of HPVs 
31/33/45/52/58 by cancer site were observed,  rang-
ing from 7.8  female anal cancer to 20.5  vaginal 
cancer.  The addition of HPVs 31/33/45/52/58 to 
HPV types included in current vaccines (HPV 16/18) 
could prevent almost 90  of HPV-positive female 
anogenital lesions worldwide [9].
　 In a report by Saraiya M et al.,  HPV DNA was 
detected in 90.6  of cervical,  91.1  of anal,  75.0  
of vaginal,  70.1  of oropharyngeal,  68.8  of vulvar,  
63.3  of penile,  32.0  of oral cavity,  and 20.9  of 
laryngeal cancers,  as well as in 98.8  of cervical 
cancers in situ (CCIS) [10].
　 HPV vaccines can potentially help to reduce HPV-
related cancers.  Globally,  approximately 70  of 
cervical cancers are attributable to genotypes 16 and/
or 18,  which are targeted by ﬁ rst-generation HPV 
vaccines (Gardasil® and Cervarix®),  and 90  to 16,  
18,  31,  33,  45,  52 or 58 which are targeted by a 
9-valent vaccine (Gardasil® 9) [11].  These genotypes 
also contribute to the majority of HPV-related vulvar 
[12-14] and vaginal cancers [13,  14].
　 The high proportion of HPV-positive non-cervical 
cancers that is attributable to HPV types 16 and 18 
underscores the potential to prevent a majority of non-
cervical HPV-related cancers among men and women 
through prophylactic HPV vaccination [15].
　 At the country level,  decision-makers are likely to 
seek data on the local genotype-speciﬁ c burden of 
HPV-related diseases for baseline information against 
which the impact of HPV vaccination can be assessed.
　 There are no previous studies of HPV-related 
anogenital cancers beyond cervical cancer in Myanmar.  
Determination of HPV status and genotypes in ano-
genital cancers may assist in patient risk stratiﬁ cation 
and prophylaxis vaccine strategy,  and may ultimately 
guide clinicians toward the optimum treatments.  The 
aim of this study was to determine the prevalence of 
HPV infection and oncogenic HPV genotypes in ano-
genital cancers by polymerase chain reaction and 
restriction fragment length of polymorphism (PCR-
RFLP).
Materials and Methods
　 This study detected the oncogenic HPV genotypes 
in anogenital cancers among men and women from a 
cross-sectional descriptive study in 2013.  A total of 
100 paraﬃ  n-embedded biopsy tissues of histologically 
conﬁ rmed anogenital cancers collected in 2008-2012 
were studied.  They included 30 penile cancers and 9 
anal cancers from Yangon General Hospital and 61 
vulvar cancers from the Central Women’s Hospital,  
Yangon,  Myanmar.  HPV DNA testing and genotyping 
were performed by PCR-RFLP.  This research proj-
ect was approved by the Ethics Review Committee on 
Medical Research Involving Human Subjects,  
Department of Medical Research (Lower Myanmar),  
(No. 32 Ethics 2012).
　 DNA extraction. DNA was isolated from sec-
104 Acta Med.  Okayama　Vol.  70,  No.  2Mu Mu Shwe et al.
tions of formalin-ﬁ xed,  paraﬃ  n-embedded anogenital 
cancer tissues.  After those tissue samples were 
treated with xylene and ethanol,  they were suspended 
in 300µL of proteinase K and incubated at 56℃ 
overnight,  then treated with Buﬀ er AL,  AW1,  and 
AW2 according to the manufacturer’s instructions 
(QIAamp DNA Mini Kit,  Qiagen,  Tokyo,  Japan).  
Finally,  DNA precipitates were eluted in 100µL buf-
fer AE.
　 HPV-DNA testing. HPV-DNA testing was 
performed using the PCR method.  Consensus sequence 
primer pairs within the E6 and E7 open reading 
frames i.e,  forward primer (pU-1M): 5’-TGTCAAA
AACCGTTGTGTCC-3’ and reverse primer (pU-2R):
5’-GAGCTGTCGCTTAATTGCTC-3’) (Oligo@ Sigma 
genosys-PCR,  Japan) were used to amplify HR-HPV 
(HPV-16,  -18,  -31,  -33,  -35,  -52b,  -58).  The reac-
tion mixture was formed using Taq polymerase 
(Applied Biosystems,  Roche,  MA,  USA),  10Xbuﬀ er,  
dNTPs,  forward and reverse primers,  distilled water 
and DNA.  The reaction mixtures were subjected to 35 
cycles of ampliﬁ cation using a thermal cycler (ASTEC,  
Japan).  Each cycle included a denaturation at 95℃ 
for 1min,  annealing at 55℃ for 1min and extension 
at 72℃ for 1min.  PCR products were detected by 
electrophoresis on 2  agarose gel,  100V,  30min and 
ethidium bromide staining.  Gel documentation (Bio-
Rad) was then performed.
　 HPV genotyping. In PCR-positive cases,  HPV 
genotyping was analyzed by PCR-RFLP method.  
HR-HPV genotypes were decided by agarose gel 
electrophoresis and ethidium bromide staining of the 
digest of the PCR product with restriction enzyme(s),  
Ava II (HPV 16,  HPV 18 and HPV 33),  Rsa I (HPV 
31),  Bgl II (HPV 52b),  Acc I (HPV 58),  and Ava I 
(HPV 35) (Wako,  Osaka,  Japan).  The enzymes were 
digested under the conditions recommended by the 
manufacturer [16].
　 Statistical analysis. Data analysis was per-
formed by using Microsoft Oﬃ  ce Excel 2007 and the 
Statistical Package for Social Sciences (SPSS-165),  
i.e.,  the SPSS full version free download (http://
en.softonic.com/s/spss-16-full-version-free-download/) 
accessed December,  2013.
Results
　 A total of 100 paraﬃ  n-embedded biopsy tissue 
samples of anogenital cancer cases collected in 2008-
2012 were studied.  They included 30 penile cancers 
and 9 anal cancers from Yangon General Hospital and 
61 vulvar cancers from the Central Women’s Hospital,  
Yangon,  Myanmar.  Most vulvar cancer patients were 
aged 50-59 years and 60-69 years (24.6  each) fol-
lowed by 40-49 years (23 ),  ≧70 years (19.7 ),  
and 30-39 years (8.2 ).  The most common age group 
of penile cancer patients was 40-49 years (26.7 ) 
followed by 30-39 years (23.3 ),  60-69 years (20 ),  
50-59 years (16.7 ),  and ≧70 years (13.3 ).  In 
anal cancers,  the most common age group was 60-69 
years (33.3 ) (Table 1).  Among the 9 cases of anal 
cancers,  7 (77.8 ) were women and 2 (22.2 ) cases 
were men.
　 Histopathological diagnosis. Histopathol-
ogically,  all cases of vulvar cancers and penile cancers 
were squamous cell carcinomas (SCC).  Among women 
who had anal cancers,  5 cases (71.4 ) were SCC and 
2 (28.6 ) were adenocarcinoma.  All men who had anal 
cancers were diagnosed as adenocarcinoma.
　 HPV DNA testing. Overall,  34  of anogenital 
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Table 1　 Proportions of vulvar,  penile,  and anal cancers by age group
Cancers
Age groups (Years)
Total
30-39 40-49 50-59 60-69 ≧70
Vulva Cancer  5 14 15 15 12  61
(8.2%) (23.0%) (24.6%) (24.6%) (19.7%) (100.0%)
Penile Cancer  7  8  5  6  4  30
(23.3%) (26.7%) (16.7%) (20.0%) (13.3%) (100.0%)
Anal Cancer  2  2  2  3  0 　9
(22.2%) (22.2%) (22.2%) (33.3%) (0%) (100.0%)
Total (Count) 14 24 22 24 16 100
(% within Anogenital Cancer) (14.0%) (24.0%) (22.0%) (24.0%) (16.0%) (100.0%)
cancer cases were positive for HPV.  Of those,  64.7  
were vulvar cancers,  23.5  penile cancers,  and 11.8  
anal cancers.  Analysis of each anogenital cancer 
revealed HPV in 44.4  of anal cancers (4/9),  36.1  
of vulvar cancers (22/61),  and 26.7  of penile can-
cers (8/30) (Fig.  1) (Table 2).  Among the 4 cases of 
HPV positive anal cancers,  75  were women diag-
nosed as squamous cell carcinoma and 25  were men 
diagnosed as adenocarcinoma.  The proportions of HPV 
in diﬀ erent histopathological grades of squamous cell 
cancers were (21 ) in well-diﬀ erentiated,  (27 ) 
moderately diﬀ erentiated,  and (52 ) poorly diﬀ eren-
tiated cases (Fig.  2).  Anogenital cancer patients 
infected with oncogenic HPV were aged 60-69 years 
(29.4 ) followed by ≧70 years and 50-59 years 
(23.5  each),  40-49 years (14.7 ),  and 30-39 years 
(8.8 ) (Fig.  3).
　 HPV genotyping. HPV genotyping was ana-
lyzed by the RFLP method.  The most prevalent HPV 
genotypes in anogenital cancers were HPV 16 (44.1 ),  
HPV 33 (32.4 ),  HPV 31 (14.7 ),  and HPV 18 
(8.8 ).  Among anal cancers,  the only genotypes were 
HPV 16 (75 ) and HPV 18 (25 ).  In vulvar can-
cers,  HPV 33 was the most common genotype (40.9 ) 
followed by HPV 16 (31.8 ),  HPV 31 (22.7 ),  and 
HPV 18 (4.6 ).  In penile cancers,  HPV 16 (62.5 ) 
was the most common genotype followed by HPV 33 
(25 ) and HPV 18 (12.5 ) (Fig.  4) (Table 3).
Discussion
　 The prevalence of HPV is signiﬁ cantly greater in 
cancers of the genital organs than in those of other 
organs.  The acquisition rate of genital HPV infections 
106 Acta Med.  Okayama　Vol.  70,  No.  2Mu Mu Shwe et al.
300bp
100bp
200bp
400bp
500bp
100bp
200bp- 
300bp 
400bp 
500bp 
12 13 14 15 16 17 18 19 20 21 22 23 24 M 25
M 1 2 3 4 5 6 7 8 9 1110
Fig. 1　 Ampliﬁ cation of HPV using pU1M/pU2R primers showing lane M,  molecular marker: 100bp ladder,  lane 1‒positive control,  
lane 11‒negative control,  lanes 2 to 9,  12,  14 to 18,  20,  23,  24‒positive for HPV DNA,  lanes 10,  13,  19 to 21,  and 22‒negative for HPV 
DNA by 2% agarose gel electrophoresis with ethidium bromide staining,  gel documentation (Bio‒Rad).  Lanes 1,  2,  5 to 9,  12,  14 to 18,  
20,  23,  and 24 about 240bp each,  and lanes 3 and 4 are each about 270bp.  Histopathological diagnosis of lanes 2 to 10 is vulvar can-
cer,  that of lanes 12 to 14 is anal cancer,  and that of lanes 15 to 24 is penile cancer.
clearly correlates with the number of lifetime sexual 
partners [17].  Based on molecular and epidemiologic 
evidence,  it is currently accepted that all cervical 
cancers and sizeable proportions of cancers of the 
anus,  oropharynx,  penis,  vagina,  and vulva are etio-
logically related to HPV infection.  Recently,  the 
incidence of HPV-related cancers such as cancers of 
the anus,  penile,  and vulva has increased substan-
tially [18].
　 Reported rates of HPV in penile cancers have 
varied from 12  to 82  while HPV is also found in 
approximately 90  of anal cancers and 50  of vulva 
cancers [19,  20].  Systematic reviews of established 
PCR techniques have found HPV in approximately 
50  of all penile SCCs [21].  Recently,  the preva-
lence of HPV in penile cancers was found to be 60.9  
in Brazil [22] and 81.5  in northern Thailand [23].  
Although the published reports on penile cancers vary 
widely in describing the prevalence of HPV,  there 
tends to be a higher prevalence in Africa and in 
Central and South America.  In this study in Myanmar,  
the prevalence of HPV in penile cancers was 26.7 ,  
which is relatively similar to the 31  and 42  rates 
reported for USA and Paraguay,  respectively;
moreover,  HPV 16 was the most common genotype in 
the present study,  similar to the ﬁ ndings of those 
studies [24,  25].
　 Vulvar cancer is rare among all gynecological can-
cers worldwide.  It mainly aﬀ ects older women,  simi-
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Table 2　 Proportion of oncogenic human papillomavirus in vulvar,  penile,  and anal cancers
HPV DNA Vulva cancer Penile cancer Anal cancer Total
HPV Positive 22 (36.1%) 8 (26.7%) 4 (44.4%) 34 (34%)
HPV Negative 39 (63.9%) 22 (73.3%) 5 (55.6%) 66 (66%)
Total 61 (100%) 30 (100%) 9 (100%) 100 (100%)
Poorly diﬀerentiated
Moderately diﬀerentiatedWell diﬀerentiated
21%
27%
52%
Poorly diﬀerentiated
Moderately diﬀerentiatedWell diﬀerentiated
43%
39%
18%
(a) HPV PCR Positive (b) HPV PCR Negative
Fig. 2　 Proportions of oncogenic HPV in diﬀ erent histopathological grades of squamous cell cancers.
HPV infected anogenital cancer in diﬀerent age groups
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
30-39 40-49 50-59 60-69 ≧70
Age Groups (Years)
HPV Negative
HPV Positive
Fig. 3　 Proportion of oncogenic human papillomavirus in ano-
genital cancers by age groups.
lar to the present study.  Gargano JW et al. reported 
that HPV was detected in 68.8  of cases of invasive 
vulvar cancer (IVC) and in 97.1  of cases of vulvar 
intraepithelial neoplasia (VIN3).  Patients with IVC 
and VIN3 diﬀ ered by median age (70 vs 55 years).  
HPV 16 was found in 48.6  of IVC and 80.9  of 
VIN3 cases [26].  De Sanjose S et al. reported on 
worldwide HPV genotype attribution in over 2000 
cases of intraepithelial and invasive lesions of the 
vulva from 39 countries,  with HPV detected in 86.7  
of VIN and 28.6  of IVC cases.  HPV 16 was the 
commonest type (72.5 ) followed by HPV 33 (6.5 ) 
and HPV 18 (4.6 ) [27].  Ngamkham J et al. showed 
that 44  of vulva cancer cases were HPV positive and 
the most common genotypes were HPV 16 followed by 
35, 33, 18,  and 58 [28].  In the present study,  the 
prevalence of HPV in vulvar cancers was 36.1 ,  
relatively similar to the above studies.  The most com-
mon genotypes in vulvar cancers were HPV 33 (40.9 ) 
and HPV 16 (31.8 ),  unlike the above studies.
　 A higher rate of HPV detection in vulvar/vaginal 
samples than in cervical samples has been reported 
[29].  Recently,  one study of indigenous women in 
Australia found that a 39  prevalence of vulvar/vagi-
nal/perianal (VVP) HR-HPV,  which was signiﬁ cantly 
higher than the 26  cervical HR-HPV prevalence.  
HPV 16 was the most common genotype detected in 
both sites (VVP 11 ,  cervical 6 ) [30].  The large 
discrepancy in HPV prevalence among anogenital sites 
may represent more persistent infection at the vulva.
　 Anal cancer accounts for only 1.5  of gastrointes-
tinal malignancies.  Anal cancer is more common in 
women than in men,  yet little is known about the natu-
ral history of HPV in women.  However,  this disease 
has now shown a steady increase in incidence,  particu-
larly in HIV-positive males.  Skamperle M et al. pointed 
out that the prevalence of HPV in anal cancers was 
90.7  and that HPV 16 was detected in 86  of anal 
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Fig. 4　 Genotyping of HPV by the restriction fragment length polymorphism method showing lane M-molecular marker: 100bp ladder,  
lanes 1,  2,  3-HPV 16,  lane 4-HPV 18,  lane 5-HPV 31,  lanes 6,  7-enzyme-undigested HPV PCR-positive cases,  lane 8-HPV 33,  by 2% 
agarose gel electrophoresis (Bio-Rad) with ethidium bromide staining.
Table 3　 Proportion of oncogenic human papillomavirus genotypes in vulvar,  penile,  and anal cancers
HPV genotypes Vulva cancer Penile cancer Anal cancer Total
HPV 16 7 (31.8%) 5 (62.5%) 3 (75.0%) 15 (44.1%)
HPV 18 1 (4.6%) 1 (12.5%) 1 (25.0%) 3 (8.8%)
HPV 31 5 (22.7%) 0 (0%) 0 (0%) 5 (14.7%)
HPV 33 9 (40.9%) 2 (25.0%) 0 (0%) 11 (32.4%)
Total 22 (100%) 8 (100%) 4 (100%) 34 (100%)
cancers [31].  Ouhoummane N et al. showed that HPV 
was detected in 92  of anal cancers.  HPV 16 (90 ) 
was the most common genotype; 60  of cases were 
women and the median age at diagnosis was 63 years 
[32].  In the present study,  most of the anogenital 
cancer patients infected with oncogenic HPV were in 
the older age groups (＞50 years),  which may repre-
sent persistent infection.  The prevalence of HPV in 
anal cancers was 44.4 ,  which is less than in other 
studies,  although the most common genotype and age 
group were HPV 16 (75 ) and 60-69 years,  similar 
to the above studies.  However,  our previous study 
found that the prevalence of HR-HPV in diﬀ erent age 
groups (especially 30-39,  40-49,  and 50-59 years) 
having cervical neoplasia especially did not diﬀ er sig-
niﬁ cantly (X2＝1.16,  p＝0.28).  A previous study 
detected the oncogenic HPV genotypes －16,  －31,  
－18,  and －58 in the majority of cervical intraepithe-
lial neoplasias and cervical cancers in Myanmar [33].  
HPV genotype 16 was the most common genotype in 
cervical neoplasias in Myanmar [33-34].
　 Regarding the HPV PCR-positive anogenital can-
cer cases,  HPV was identiﬁ ed mostly in poorly dif-
ferentiated squamous cell carcinoma (SCC) (52 ) 
followed by moderately diﬀ erentiated SCC (27 ) and 
well-diﬀ erentiated SCC (21 ).  Regarding the HPV 
PCR-negative anogenital cancer cases,  HPV was not 
detected in well-diﬀ erentiated SCC (43 ) followed by 
moderately (39 ) and poorly (18 ) diﬀ erentiated 
SCC.  In the present study,  although oncogenic HPV 
was associated with all histological grades of SCC of 
anogenital cancers,  poorly diﬀ erentiated grades of 
SCC of anogenital cancers are more commonly associ-
ated with oncogenic HPV infection.  We could not ﬁ nd 
an association between histopathological grades and 
HPV genotypes.  
　 The variability of HPV detection in not only ano-
genital but also cervical cancers may depend on the 
diﬀ erent HPV detection methods,  the types of speci-
mens used (such as fresh tissue or formalin-ﬁ xed par-
aﬃ  n-embedded tissue),  and also the geographic varia-
tions in HPV distribution.  This subject needs further 
investigation,  including searches for possible environ-
mental and/or genetic factors that may impair host 
immunity.
　 In conclusion,  this study identiﬁ ed that the most 
prevalent genotype in anal and penile cancers was 
HPV 16,  which is vaccine-preventable.  In vulvar 
cancers,  on the other hand,  HPV 33 and HPV 16 
were the most common genotypes.  This is the ﬁ rst 
report of evidence-based oncogenic HPV genotypes in 
anogenital cancers among men and women in Myanmar.  
This research provides valuable information for under-
standing the incidenceof HPV-associated cancers of the 
anus,  penis,  and vulva and for considering the eﬀ ec-
tiveness of prophylactic HPV vaccination.
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